Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: Randomised trial

BMJ (Online)

Volumn 339, Issue 7715, 2009, Pages 283-

  Achan, Jane ^a   Tibenderana, James K ^b,c   Kyabayinze, Daniel ^b   Mangen, Fred Wabwire ^a   Kamya, Moses R ^a   Dorsey, Grant ^d   D'Alessandro, Umberto ^e   Rosenthal, Philip J ^d   Talisuna, Ambrose O ^a,e  

^a MAKERERE UNIVERSITY   (Uganda)

^b MALARIA CONSORTIUM   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Design randomised, open label effectiveness study

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; HEMOGLOBIN; QUININE SULFATE;

ANOREXIA; ARTICLE; CAREGIVER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; EVENING DOSAGE; FOLLOW UP; GAMETOCYTE; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MORNING DOSAGE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; TREATMENT FAILURE; UGANDA; VOMITING;

ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MEDICATION ADHERENCE; QUININE; TREATMENT OUTCOME;

EID: 68149084942     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b2763     Document Type: Article

References (37)

1. World Health Organization. Antimalarial drug combination therapy. Report of WHO technical consultation. WHO/CDS/RBM/2001.35. Geneva: WHO, 2001.
2. Meshnick SR, Dobson MJ. The history of antimalarial drugs. Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery. In: Rosenthal PJ, ed. Totowa, NJ: Humana Press, 2001:15-25.
3. World Health Organization. WHO guidelines for the treatment of malaria. WHO/HTM/MAL/2006.Geneva: WHO, 2006:1108.
4. World Health Organization.Global antimalarial drug policies database - AFRO. Antimalarial treatment policies for P falciparum and P vivax by country in WHO Africa region. www.who.int/malaria/amdp-afro.html (accessed 9 Sep 2008).
5. Zurovac D, Tibenderana JK, Nankabirwa J, Ssekitooleko J, Njogu NJ, Rwakimari JB, et al. Malaria case-management under artemetherlumefantrine treatment policy in Uganda. Malar J 2008;7:181.
6. Kofoed PE, Ursing J, Rodrigues A, Rombo L. Failures following initial treatment for uncomplicated malaria: quinine as second line therapy. J Pediatr Infect Dis 2007;2:121-126 (Pubitemid 47422485)
7. Adam I, Salih I, Elbashir MI. Quinine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan. Trans R Soc Trop Med Hyg 2005;99:736-738 (Pubitemid 41150669)
8. Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 2000;44:2395-2398 (Pubitemid 30650885)
9. McGready R, Ashley EA, Moo E, Cho T, Barends M, Hutagalung R, et al. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J Infect Dis 2005;192:846-853 (Pubitemid 41193082)
10. Adegnika AA, Breitling LP, Agnandji ST, Chai SK, Schutte D, Oyakhirome S, et al. Effectiveness of quinine monotherapy for the treatment of plasmodium falciparum malaria in pregnant women in Lambarene, Gabon. Am J Trop Med Hyg 2005;73:263-266 (Pubitemid 41278694)
11. Roche J, Guerra-Neira A, Raso J, Benito A. Surveillance of in vivo resistance of Plasmodium falciparum to antimalarial drugs from 1992 to 1999 in Malabo (Equatorial Guinea). Am J Trop Med Hyg 2003;68:598-601.
12. Ache A, Escorihuela M, Vivas E, Paez E, Miranda L,Matos A, et al. In vivo drug resistance of falciparum malaria in mining areas of Venezuela. Trop Med Int Health 2002;7:737-743
13. Parola P, Ranque S, Badiaga S, Niang M, Blin O, Charbit JJ, et al. Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travellers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother 2001;45:932-935 (Pubitemid 32182048)
14. Quashie NB, Duah NO, Abuaku B, Koram KA. The in-vitro susceptibilities of Ghanaian Plasmodium falciparum to antimalarial drugs. Ann Trop Med Parasitol 2007;101:391-398 (Pubitemid 47488127)
15. Menard D, Yapou F, Manirakiza A, Djalle D, Matsika-Claquin MD, Talarmin A. Polymorphisms in pfcrt, pfmdr1, dhfr genes and in vitro responses to antimalarials in plasmodium falciparum isolates from Bangui, Central African Republic. AmJ TropMed Hyg 2006;75:381-387
16. Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, et al. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of plasmodium falciparum isolates. Am J Trop Med Hyg 2006;75:146-151 (Pubitemid 351627584)
17. Pradines B, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, et al. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol 2006;44:2404-2408 (Pubitemid 44092404)
18. Agnamey P, Brasseur P, Eldin de Pecoulas P, Vaillant M, Olliaro P. Plasmodium falciparum in vitro susceptibility to antimalarial drugs in Casamance (south western Senegal) during the first 5 years of routine use of artesunate-amodiaquine. Antimicrob Agents Chemother 2006;50:1531-1534
19. Tinto H, Rwagacondo C, Karema C, Mupfasoni D, Vandoren W, Rusanganwa E, et al. In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda. Trans R Soc Trop Med Hyg 2006;100:509-514
20. Pukrittayakamee S, Wanwimolruk S, Stepniewska K, Jantra A, Huyakorn S, Looareesuwan S et al. Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob Agents Chemother 2003;47:3458-3463 (Pubitemid 37345704)
21. Fungladda W, Honrado ER, Thimasarn K, Kitayaporn D, Karbwang J, Kamolratanakul P, et al. Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull World Health Organ 1998;76(suppl 1):59-66. (Pubitemid 128685315)
22. Taylor WRJ, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004;27:25-61.
23. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000;94:1-90.
24. World Health Organization. WHO toxicity grading scale for determining the severity of adverse events. Geneva: WHO. www. icssc.org/Documents/Resources/ AEManual2003AppendicesFebruary-06-2003%20final.pdf (accessed 10 Apr 2007).
25. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 1995;52:565-568
26. Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, Rosenthal PJ, et al. Validation of microsatellite markers for use in genotyping polyclonal plasmodium falciparum infections. Am J Trop Med Hyg 2006;75:836-842 (Pubitemid 351627527)
27. World Health Organization. The use of antimalarial drugs - report of a WHO informal consultation. WHO/CDS/RBM/2001.33. Geneva: WHO, 2000.
28. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, et al. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg 2004;71:525-530 (Pubitemid 39601144)
29. Mayxay M, Barends M, Brockman A, Jaidee A, Nair S, Sudimack D, et al. In vitro antimalarial drug susceptibility and pfcrt mutation among fresh plasmodium falciparum isolates from the Lao PDR (Laos). Am J Trop Med Hyg 2007;76:245-250
30. Chaijaroenkul W, Bangchang KN, Mungthin M, Ward SA. In vitro antimalarial drug susceptibility in Thai border areas from 1998-2003. Malar J 2005;4:37.
31. Legrand E, Volney B, Meynard B, Mercereau-Puijalon O, Esterre P. In vitromonitoring of Plasmodium falciparum drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob Agents Chemother 2008;52:288-298
32. Kofoed PE, Mapaba E, Lopes F, Pussick F, Aaby P, Rombo L. Comparison of 3, 5 and 7 days' treatment with Quinimax for falciparum malaria in Guinea-Bissau. Trans R Soc Trop Med Hyg 1997;91:462-464 (Pubitemid 27421244)
33. Piola P, Fogg C, Bajunirwe F,Biraro S,Grandesso F, Ruzagira E, et al. Supervised versus unsupervised intake of six-dose artemetherlumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005;365:1467-1473 (Pubitemid 40591691)
34. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, et al. Amodiaquine alone,amodiaquine+sulfadoxinepyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005;365:1474-1480 (Pubitemid 40591692)
35. Depoortere E,Guthmann JP, Sipilanyambe N, Nkandu E, Fermon F, Balkan S, et al Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia. Trop Med Int Health 2004;9:62-67 (Pubitemid 38178013)
36. Oyakhirome S, Pötschke M, Schwarz NG, Dörnemann J, Laengin M, Salazar CO, et al. Artesunate-amodiaquine combination therapy for falciparum malaria in young Gabonese children. Malar J 2007;6:29. (Pubitemid 46474682)
37. Depoortere E, Guthmann JP, Presse J, Sipilanyambe N, Nkandu E, Balkan S, et al. Efficacy and effectiveness of the combination of sulfadoxine/ pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia. Trop Med Int Health 2005;10:139-145 (Pubitemid 40269163)